Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-10-23
2007-10-23
Shibuya, Mark L. (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S631000
Reexamination Certificate
active
10718846
ABSTRACT:
The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer's disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.
REFERENCES:
patent: 4788179 (1988-11-01), Flohe et al.
patent: 5091404 (1992-02-01), Elgebaly
patent: 5321030 (1994-06-01), Kaddurah-Daouk et al.
patent: 5324731 (1994-06-01), Kaddurah-Daouk et al.
patent: 5492930 (1996-02-01), Coffin
patent: 5741661 (1998-04-01), Goldin et al.
patent: 6169115 (2001-01-01), Kaddurah-Daouk
patent: WO 90/09192 (1990-08-01), None
patent: WO 92/08456 (1992-05-01), None
patent: WO 94/16687 (1994-08-01), None
patent: WO 94/17794 (1994-08-01), None
Annesley, T., et al., “Cyclocreatine Phosphate as a Substitute for Creatine Phosphate in Vertebrate Tissue, Energetic Considerations,”Biochem. Biophys. Res. Commun., 1977; 74:185-90.
Annesley, T., et al., “Formation and Utilization of Novel High Energy Phosphate Reservoirs in Ehrlich Ascites Tumor Cells,”J. Biol. Chem., 1978; 253(22):8120-5
Beal, M., “Aging, Energy, and Oxidative Stress in Neurodegenerative Diseases,”Ann. Neurol., 1995; 38:357-66.
Beal, M., “Does Impairment of Energy Metabolism Result in Excitotoxic Neuronal Death in Neurodegenerative Illnesses?”Ann. Neurol., 1992; 31:119-30.
Beal, M. et al., “Age-Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate,”J. Neurochem., 1993; 61:1147-50.
Bertolini, et al., Chemical Abstracts AN 1982:49622.
Brady, S., et al., “Nerve-Specific Enolase and Creatine Phosphokinase in Axonal Transport: Soluble Proteins and the Axoplasmic Matrix,”Cell, 1981; 23:515-23.
Brouillet, E., et al., “Chronic Mitochondrial Energy Impairment Produces Selective Striatal Degeneration and Abnormal Choreiform Movements in Primates,”PNAS, 1995; 92:7105-9.
Browne, S., et al., “Oxidative Damage and Metabolic Dysfunction in Huntington's Disease: Selective Vulnerability of the Basal Ganglia,”Ann. Neurol., 1997; 41:646-53.
Burbaeva, G.S., et al., “Decreased Level of Immunoreactive Phosphokinase BB Isoenzymes in the Brain of Patients with Schizophrenia and Senile Dementia of the Alzheimer Type,”Zh. Nevropatol. Psikhiatr Im S S Korsakova, 1990; 90(7):85-7.
Cadoux-Hudson, T., et al., “Imaging of Human Brain Creatine Kinase Activity in Vivo,”FASEB J., 1989; 3:2660-6.
Carter, A.J., et al., “Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices,”J Neurochem. 1995; 64(6):2691-9.
Chandler, W., et al., “Regional Creatine Kinase, Adenylate Kinase, and Lactate Dehydrogenase in Normal Canine Brain,”Stroke, 1988; 19:251-5.
Cramer, F., et al., “Die Synthese der Argininphosphorsäure und die Reaktion von Isoureidophosphonaten mit Aminen,”Chem. Ber., 1962, 95:1670-82.
De Leon, M., et al., “Identification of Transcriptionally Regulated Genes After Sciatic Nerve Injury,”J. Neurosci. Res., 1991: 29:437-48.
Erecinska, M., et al., “ATP and Brain Function,”J. Cerebr. Bloof Flow and Metabolism, 1989; 9:2-19.
Friedhoff, A., et al., “Creatine Kinase Isoenzyme Associated with Synaptosomal Membrane and Synaptic Vesicles,”Life Sci., 1977; 20:867-74.
Goodman & Gilman, The Pharmcological Basis of Therapeutics, 1980, 6thEd. (MacMillan Pub.); 5-10.
Griffiths, G., et al., “Accumulation of Analog of Phosphocreatine in Muscle of Chicks Fed 1-Carboxymethyl-2-iminoimidazolidine (Cyclocreatine),”J. Biol. Chem., 1976; 251(7):2049-54.
Gu, M., et al., “Mitochondrial Defect in Huntington's Disease Caudate Nucleus,”Ann. Neurol., 1996; 39:385-9.
Gurney, M., et al., “Motor Neuron Degeneration in Mice That Express a Human Cu,Zn Superoxide Dismutase Mutation,”Science, 1994; 264:1772-5.
Hemmer, W., et al., “Functional Aspects of Creatine Kinase in Brain,”Dev. Neuroscience, 1993; 15:249-260.
Hagenfeldt, L., et al., “Creatine Treatment in MELAS,”Muscle and Nerve. 1994; 10:1236-7.
Hemmer, W., et al., “Creatine Kinase Isoenzymes in Chicken Cerebellum: Specific Localization of Brain-type Creatine Kinase in Bergmann Glial Cells and Muscle-type Creatine Kinase in Purkinje Neurons,”Eur. J. Neuroscience, 1994; 6:538-49.
Henshaw, R., et al., “Malonate Produces Striatal Lesions by Indirect NMDA Receptor Activation,”Brain Research, 1994; 647:161-6.
Hertz, L., et al., “Energy Metabolism at the Cellular Level of the CNS,”Can. J. Physiol. Pharmacol., 1992, 70:S145-57.
Ito, M., “The Cellular Basis of Cerebellar Plasticity,”Corr. Opin. Neurobiol., 1991; 1:616-20.
Jenkins, B., et al., “Evidence for Impairment of Energy Metabolism in Vivo in Huntington's Disease Using Localized 1H NMR Spectroscopy,”Neurology, 1993; 43:2689-95.
Kahn, M.A., “Effect of Calcium on Creatine Kinase Activity of Cerebellum,”Histochem., 1976; 48:29-32.
Lillie, J., et al., “Cyclocreatine (1-Carboxymethyl-2-iminoimidazolidine) Inhibits Growth of a Broad Spectrum of Cancer Cells Derived from Solid Tumors,”Cancer Res., 1993; 53:3172-8.
Lim, L., et al., “Neurone-Specific Enolase and Creatine Phosphokinase are Protein Components of Rat Brain Synaptic Plasma Membranes,”J. Neurochem., 1983; 41:1177-82.
LoPresti, P., et al., “Direct Determination of Creatine Kinase Equilibrium Constants with Creatine or Cyclocreatine as Substrate,”Biochem. Biophys. Acta., 1989; 998:317-20.
Lowe, G., et al., “Evidence for an Associative Mechanism in the Phosphoryl Transfer Step Catalyzed by Rabbit Muscle Creatine Kinase,”J. Biol. Chem., 1980; 225(9):3944-51.
Maker, H., et al., “Regional Changes in Cerebellar Creatine Phosphate Metabolism During Late Maturation,”Exp. Neurol., 1973; 38:295-300.
Manos, P., et al., “Creatine Kinase Activity in Postnatal Rat Brain Development and in Cultured Neurons, Astrocytes, and Oligodendrocytes,”J. Neurochem., 1991; 56:2101-7.
Marletta, M., et al., “Affinity Labeling of Creatine Kinase by N-(2,3-Epoxypropyl)-N-amidinoglycine,”J. Biol. Chem., 1979; 254(6):1879-86.
McLaughlin, A., et al., “Specificity of Creatine Kinase for Guanidino Substrates,”J. Biol. Chem., 1972; 247(13):4382-8.
Molloy, G., et al., “Rat Brain Creatine Kinase Messenger RNA Levels are High in Primary Cultures of Brain Astrocytes and Oligodendrocytes and Low in Neurons,”J. Neurochem., 1992; 59:1925-32.
Newman, E., “Regulation of Potassium Levels by Glial Cells in the Retina,”Trends Neuroscience, 1985; 8:156-9.
Oblinger, M., et al., “Cytotypic Differences in the Protein Composition of the Axonally Transported Cytoskeleton in Mammalian Neurons,”J. Neurol., 1987; 7(2):453-62.
Orlovskaia, D.D., et al., “Neuromorphology and Neurochemistry of Senile Dementias in the Light of Studies on Glial Response,”Ves
Beal M. Flint
Daouk Ghaleb
Kaddurah-Daouk Rima
Avicena Group, Inc.
Hanley, Esq. Elizabeth A.
Lahive & Cockfield LLP
Shibuya Mark L.
Sooros, Esq. Cynthia M.
LandOfFree
Use of creatine or creatine analogs for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of creatine or creatine analogs for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of creatine or creatine analogs for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3899060